De-Qian Jiang

The Second Xiangya Hospital of Central South University, Ch’ang-sha-shih, Hunan, China

Are you De-Qian Jiang?

Claim your profile

Publications (2)4.02 Total impact

  • Li-Ya Ji · De-Qian Jiang · Ni-Ni Dong
    [Show abstract] [Hide abstract]
    ABSTRACT: Increasing evidence suggests that microRNAs(miRs) play a crucial role in the cardiovascular system, and recent studies have revealed a significant role of miRs in vascular biology and disease, miR-145 is one of the most-studied miRs, and especially in the vascular smooth muscle cell (VSMCs) proliferation, differentiation, and phenotypic switching. In cardiovascular system, miR-145 is not only important for heart and vascular development but also plays an essential role in cardiac pathological factors, such as hypertrophy, and ischemia. However, its potential role in microvasculature has not been systematically evaluated yet. We are just beginning to understand the regulation of miR in vascular biology. In particular, the miR biogenesis and regulatory pathways in the vascular system have not yet been well characterized, This review focuses on the basic biology and mechanism of action of miR-145 specifically pertaining to microvascular development, pericyte and disease, In addition it addresses the potential for miR-145 to be used therapeutically in the treatment of microvascular disease.
    No preview · Article · Jun 2013 · Pharmazie
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: Epoxyeicosatrienoic acids (EETs) have been shown to play a role in cardiovascular protection by reducing ischemia reperfusion injury, producing anti-inflammatory effects, and promoting angiogenesis. EETs are regulated through conversion to less active corresponding diols by soluble epoxide hydrolase (sEH). Inhibition of sEH enhances the beneficial properties of EETs and has been investigated as a possible treatment for cardiovascular diseases. Content: sEH inhibitors (sEHIs) have anti-inflammatory effects by stabilizing anti-inflammatory EETs. Additionally, sEHIs strongly inhibit and reverse cardiac hypertrophy. sEHIs have been shown to protect myocardial cells from ischemia-reperfusion injury, treat atherosclerosis and prevent the development of hypertension. sEHIs promote blood vessels to release bradykinin via an EET-mediated STAT3 signaling pathway to inhibit elicit tolerance to ischemia. Summary: Inhibition of sEH has been shown to improve several aspects of cardiovascular disease, including inflammation, hypertension, cardiac hypertrophy and atherosclerosis. For this reason, sEHIs are a promising new pharmaceutical for the treatment of cardiovascular disease.
    No preview · Article · Feb 2012 · Current Vascular Pharmacology